FluoGuide A/S is a clinical stage biotechnology company focused on developing drugs for maximizing surgical outcomes by making cancer fluorescent.

New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

New exchange: Nasdaq First North


Morten Albrechtsen - CEO (Chief Executive Officer) FluoGuide

Morten Albrechtsen

CEO (Chief Executive Officer)

Morten Albrechtsen is an MD and BBA (‘HD’ in marketing, CBS). Morten is a seasoned entrepreneur with a strong medical, commercial and financial background. The expertise is gained within a broad range of therapeutic areas and with both drugs and devices. The development expertise includes all stages, pre-clinical, clinical and post-market development, and with various disciplines. The commercial expertise is gained internationally and includes sales through partners, affiliates and direct to patients, hospitals and direct to end-users. It also includes business development with licensing and corporate deals. Previously, Morten has developed and launched new health care products and concepts internationally, e.g. in Nycomed Pharma, now Takeda Pharmaceuticals Ltd. (pain control), Nanovi (brought a new cancer product to the market in Europe and prepared it for US) and Boehringer Ingelheim GmbH (hospital sales, cardiovascular, stroke female health and pain control). Morten has also a strong experience from early clinical development in e.g. Enkam A/S (CNS drug development including medicines for Alzheimer’s disease, Parkinson’s disease and depression) and several others.

Number of FluoGuide shares 1,488,610 ( owned via Wexotec ApS) and privately 110,000 warrants

Henrik Hang - CFO (Chief Financial Officer) FluoGuide

Henrik Hang

CFO (Chief Financial Officer)

Henrik Hang holds a BSc in finance from University of Linné in Sweden and has experience from life science start-ups and the health care sector, including previous roles as CFO. The primary focus of his career has been financing, including IPOs, investor relations, business development, as well as financial, strategical and business planning.­

Number of FluoGuide shares  0 and 0 warrants.

Andreas Kjaer - CSO & CMO FluoGuide

Andreas Kjaer


Andreas Kjaer, is an MD, PhD, DMSc and professor at the University of Copenhagen and chief physician at Rigshospitalet, the National University Hospital of Denmark. His research is focused on molecular imaging with PET, PET/MRI and OPTICAL IMAGING in cancer and cardiovascular disease and his achievements include development of several new tracers that have reached first-in-humans clinical use. He is the holder of an ERC Advanced Grant, has published more than 400 peer-review articles and has received numerous prestigious scientific awards over the years. Andreas Kjaer also has an MBA from Copenhagen Business School.

Number of FluoGuide shares  2,126,107 and 105,000 warrants (Partly owned via Life Science Aps)

Grethe Nørskov Rasmussen - CDO (Chief Development officer) FluoGuide

Grethe Nørskov Rasmussen

CDO (Chief Development officer)

Grethe Nørskov Rasmussen holds an M.Sc and PhD. Grethe Rasmussen is an experienced product developer with a profound understanding of CMC and former Senior Vice President Product Development at Ascendis Pharma A/S, where Rasmussen worked for over 10 years. Previously, Grethe Rasmussen served as Vice President for Protein Science at Maxygen, Inc. and later as Managing Director for the Danish subsidiary of Maxygen. Prior to joining Maxygen, Dr. Rasmussen held various positions at Novo Nordisk A/S, a global healthcare company, where she contributed to research and development. Dr. Rasmussen holds a PhD in Biochemistry from the Danish Technical University.

Number of FluoGuide shares 373,185 and 32,500 warrants

Dorthe Grønnegaard Mejer - VP Clinical Development FluoGuide

Dorthe Grønnegaard Mejer

VP Clinical Development

Dorthe Grønnegaard Mejer has a M.Sc. in Pharmaceutical Sciences from Copenhagen University. She has previously held several positions across different clinical development disciplines as well as positions within clinical oncology development in other biotech companies such as Genmab, Larix, Orphazyme and Oncology Venture.

Number of FluoGuide shares 724 and 19,300 warrants